Post by Invenra

We're excited to attend and serve as lead partner of the T-Cell Engager Therapeutics Summit in San Diego! Our team will be sharing the latest advances in T-cell engager development, including a presentation from Joe Goldufsky on how optimization of TAA/CD3/CD28 T-Body™ trispecific antibodies can drive superior tumor-directed T-cell engagement while minimizing off-tumor toxicity. The work demonstrates how CD28 co-stimulation preserves T-cell function, rescues exhausted T cells, and supports durable antitumor responses. We will also be presenting posters including: • From High-Quality mAb Discovery to Multispecific Therapeutics: Discovered. Designed. Delivered. • High-Throughput Screening of Bispecific ADCs: Evaluation of a 5-Target Matrix Using the B-Body Platform. Attending the summit? We'd love to connect and discuss how Invenra's antibody discovery and multispecific engineering platforms are supporting the development of next-generation immunotherapies! #TCellEngagers #Immunotherapy #AntibodyDiscovery #BispecificAntibodies #TrispecificAntibodies #CancerResearch #Biotech #DrugDiscovery